Medical management of breast cancer in BRCA mutation carriers

Soley Bayraktar, Banu K. Arun

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

BRCA mutation-associated breast cancer differs from sporadic breast cancer as studies show that they have higher risk of breast and ovarian cancer and also has differential sensitivity to chemotherapeutic agents. It is an accepted general opinion that breast cancer outcome for BRCA1/2 mutation carriers is at least as good as for non-carriers. On the other hand, we know that BRCA1 and BRCA2 mutation carriers have a lifetime risk of breast cancer in the ranges 47-66% and 40-57%, respectively. Additionally, women with BRCA mutation-associated breast cancer also have an elevated risk of other or secondary malignancies. Therefore, identification of those who might have a mutation is important so that genetic counseling, testing, screening, and prevention strategies can be applied. This article reviews the sensitivity of BRCA-defective breast cancer cell lines to platinum cytotoxic compounds, poly (ADP-ribose) polymerase inhibitors, and endocrine therapy is reviewed.

Original languageEnglish (US)
Title of host publicationManaging BRCA Mutation Carriers
PublisherSpringer International Publishing
Pages135-150
Number of pages16
ISBN (Electronic)9783319591988
ISBN (Print)9783319591971
DOIs
StatePublished - Jul 13 2017

Keywords

  • BRCA1
  • BRCA2
  • Breast cancer
  • Hereditary breast cancer
  • Platinums
  • Prevention
  • Prophylactic mastectomy
  • Prophylactic oophorectomy PARP inhibitors
  • Risk models

ASJC Scopus subject areas

  • General Medicine
  • General Biochemistry, Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Medical management of breast cancer in BRCA mutation carriers'. Together they form a unique fingerprint.

Cite this